WoodTrust Financial Corp Sells 3,500 Shares of Evolent Health, Inc. (NYSE:EVH)

WoodTrust Financial Corp trimmed its holdings in Evolent Health, Inc. (NYSE:EVH) by 7.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,650 shares of the technology company’s stock after selling 3,500 shares during the quarter. WoodTrust Financial Corp’s holdings in Evolent Health were worth $1,206,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of EVH. RA Capital Management L.P. boosted its position in shares of Evolent Health by 125.0% in the first quarter. RA Capital Management L.P. now owns 5,736,132 shares of the technology company’s stock valued at $188,088,000 after acquiring an additional 3,187,000 shares during the period. William Blair Investment Management LLC lifted its position in Evolent Health by 35.2% in the second quarter. William Blair Investment Management LLC now owns 5,026,043 shares of the technology company’s stock worth $96,098,000 after purchasing an additional 1,308,376 shares during the period. First Light Asset Management LLC lifted its position in Evolent Health by 401.5% in the second quarter. First Light Asset Management LLC now owns 1,445,305 shares of the technology company’s stock worth $27,634,000 after purchasing an additional 1,157,124 shares during the period. Engaged Capital LLC lifted its position in Evolent Health by 26.1% in the second quarter. Engaged Capital LLC now owns 4,111,458 shares of the technology company’s stock worth $78,611,000 after purchasing an additional 850,000 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Evolent Health by 24.8% in the second quarter. Bank of New York Mellon Corp now owns 2,048,341 shares of the technology company’s stock worth $39,164,000 after purchasing an additional 406,837 shares during the period.

Evolent Health Stock Up 5.1 %

Evolent Health stock opened at $24.78 on Thursday. The stock has a 50-day simple moving average of $27.35 and a 200 day simple moving average of $24.98. The company has a quick ratio of 1.08, a current ratio of 1.08 and a debt-to-equity ratio of 0.57. Evolent Health, Inc. has a 12-month low of $17.98 and a 12-month high of $35.00.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Thursday, August 8th. The technology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.09. The firm had revenue of $647.10 million during the quarter, compared to analysts’ expectations of $636.46 million. Evolent Health had a positive return on equity of 8.47% and a negative net margin of 3.16%. The company’s quarterly revenue was up 37.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.06 EPS. On average, equities research analysts predict that Evolent Health, Inc. will post 0.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

EVH has been the subject of several research reports. JPMorgan Chase & Co. raised their target price on Evolent Health from $36.00 to $45.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Stephens restated an “overweight” rating and issued a $42.00 target price on shares of Evolent Health in a research note on Tuesday, July 30th. JMP Securities reduced their target price on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating on the stock in a research note on Friday, August 9th. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 target price on shares of Evolent Health in a research note on Tuesday, October 8th. Finally, Citigroup reduced their target price on shares of Evolent Health from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $38.60.

Insiders Place Their Bets

In other Evolent Health news, COO Emily Ann Rafferty sold 8,861 shares of the business’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $265,830.00. Following the completion of the sale, the chief operating officer now directly owns 63,408 shares of the company’s stock, valued at approximately $1,902,240. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO Seth Blackley sold 187,904 shares of the company’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total value of $5,637,120.00. Following the completion of the sale, the chief executive officer now directly owns 411,924 shares of the company’s stock, valued at $12,357,720. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Emily Ann Rafferty sold 8,861 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $265,830.00. Following the completion of the sale, the chief operating officer now directly owns 63,408 shares of the company’s stock, valued at approximately $1,902,240. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 307,291 shares of company stock valued at $9,290,385. 1.60% of the stock is currently owned by insiders.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.